Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01263470
First received: December 17, 2010
Last updated: February 1, 2012
Last verified: February 2012

December 17, 2010
February 1, 2012
January 2007
December 2007   (final data collection date for primary outcome measure)
Change From Baseline in Glycosylated Hemoglobin (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
Change from Baseline in Glycosylated Hemoglobin (Week 12) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline
Complete list of historical versions of study NCT01263470 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Glycosylated Hemoglobin (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
  • Change From Baseline in Glycosylated Hemoglobin (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 2). [ Time Frame: Baseline and Week 2 ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting Plasma Glucose (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline.
  • Change From Baseline in Fasting C-peptide (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.
  • Change From Baseline in Fasting C-peptide (Week 4). [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.
  • Change From Baseline in Fasting C-peptide (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.
  • Change From Baseline in Fasting C-peptide (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.
  • Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
  • Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC (0-2)). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
  • Change From Baseline in Insulin Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC(0-2)). [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
  • Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
  • Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)). [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
  • Change from Baseline in Glycosylated Hemoglobin (Week 2). [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline
  • Change from Baseline in Glycosylated Hemoglobin (Week 4) [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline
  • Change from Baseline in Glycosylated Hemoglobin (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline
  • Change from Baseline in Fasting Plasma Glucose (Week 2). [ Time Frame: Baseline and Week 2 ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline
  • Change from Baseline in Fasting Plasma Glucose (Week 4) [ Time Frame: Baseline and Week 4. ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
  • Change from Baseline in Fasting Plasma Glucose (Week 8). [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
  • Change from Baseline in Fasting Plasma Glucose (Week 12) [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline
  • Change from Baseline in Fasting C-peptide (Week 2) [ Time Frame: Baseline and Week 2. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.
  • Change from Baseline in Fasting C-peptide (Week 4). [ Time Frame: Baseline and Week 4 ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.
  • Change from Baseline in Fasting C-peptide (Week 8). [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline
  • Change from Baseline in Fasting C-peptide (Week 12). [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.
  • Change from Baseline in Blood Glucose Insulin. [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the value of blood glucose insulin collected at week 12 or final visit and blood glucose insulin collected at baseline as measured by the meal tolerance test.
  • Change from Baseline in Insulin. [ Time Frame: Baseline and Week 12 ] [ Designated as safety issue: No ]
    The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test.
  • Change from Baseline in C-peptide. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test.
  • Change from Baseline in Glucagons. [ Time Frame: Baseline and Week 12. ] [ Designated as safety issue: No ]
    The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline as measured by the meal tolerance test.
Not Provided
Not Provided
 
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan

The purpose of this study was to evaluate the dose-response relationships of alogliptin, once daily (QD) to an α-glucosidase inhibitor, three times daily (TID), to determine the optimal clinical dose for type 2 diabetic patients.

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

To evaluate the long-term safety and efficacy of alogliptin, participants in the present study could enter a long-term extension study SYR-322/OCT-001 (NCT01263496) that was planned separately.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Alogliptin
    Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
    Other Name: SYR-322
  • Drug: Alogliptin
    Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
    Other Name: SYR-322
  • Drug: Voglibose
    Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
    Other Names:
    • Voglib
    • BASEN®
  • Drug: Placebo
    Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: Alogliptin 6.25 mg QD
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 12.5 mg QD
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 25 mg QD
    Intervention: Drug: Alogliptin
  • Experimental: Alogliptin 50 mg QD
    Intervention: Drug: Alogliptin
  • Active Comparator: Voglibose 0.2 mg TID
    Intervention: Drug: Voglibose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
480
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • A glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of screening(Week −4).
  • A HbA1c differences within 10.0%* (*rounded off to the first decimal point) at the start of screening (Week −8) and 4 weeks after the start of screening (Week −4) from the HbA1c value at the start of screening.
  • Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of screening (Week −8).

Exclusion Criteria:

  • Received any antidiabetic drug within the last 4 weeks before the start of screening (Week −8) or during screening.
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01263470
SYR-322/CCT-001, U1111-1118-3752
No
Takeda
Takeda
Not Provided
Study Director: Professor, Department of Medicine Kawasaki Medical School
Takeda
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP